Skip to main content
ATOSSA THERAPEUTICS, INC. logo

ATOSSA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ATOS ISIN · US04962H5063 US Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2013-08-15 Declaration of Voting R…
Country US United States of America
Listing US ATOS

About ATOSSA THERAPEUTICS, INC.

https://atossatherapeutics.com/

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative medicines for areas of significant unmet medical need, with a primary focus on oncology. The company is dedicated to addressing the full continuum of breast cancer care. Its lead program is centered on (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen through clinical development for multiple breast cancer indications, including metastatic disease, aiming to provide a therapeutic with a potentially improved efficacy and tolerability profile.

Recent filings

Filing Released Lang Actions
8-K/A
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K/A filed with the SEC, amending a previous Form 8-K related to the final voting results of the company's 2013 Annual Meeting of Stockholders. The amendment specifically discloses the company's decision on the frequency of future stockholder advisory votes on executive compensation (Say on Pay). The content focuses on voting results and decisions about shareholder votes rather than presenting financial data or detailed reports. The document length is 3407 characters, which is relatively short and primarily serves as an announcement of voting results and company decisions regarding shareholder votes. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2013-08-15 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 14, 2013, by Atossa Genetics Inc. It announces the company's second quarter financial results via a press release attached as Exhibit 99.1. The text explicitly states that the press release is incorporated by reference and is not considered filed for certain legal purposes. The document itself is a current report announcing financial results, not the full financial report or detailed financial statements. The length is 3135 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, initial announcements of quarterly or periodical financial results (key highlights only) correspond to the Earnings Release (ER) category. Therefore, this document should be classified as an Earnings Release (ER).
2013-08-14 English
10-Q
Interim / Quarterly Report Q2 2013
2013-08-14 English
PRIMARY DOCUMENT
Director's Dealing
2013-06-27 English
PRIMARY DOCUMENT
Director's Dealing
2013-06-06 English
FORM 10-Q
Interim / Quarterly Report Q1 2013
2013-05-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.